Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
212
-
Total 13F shares, excl. options
-
61.6M
-
Shares change
-
-2.58M
-
Total reported value, excl. options
-
$2.55B
-
Value change
-
-$145M
-
Put/Call ratio
-
0.76
-
Number of buys
-
127
-
Number of sells
-
-86
-
Price
-
$41.41
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q3 2022
259 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q3 2022.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 212 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.6M shares
of 96M outstanding shares and own 64.22% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (6.16M shares), WELLINGTON MANAGEMENT GROUP LLP (6.05M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.76M shares), BlackRock Inc. (3.93M shares), Capital International Investors (3.39M shares), Clearbridge Investments, LLC (2.76M shares), T. Rowe Price Investment Management, Inc. (2.61M shares), STATE STREET CORP (2.56M shares), RTW INVESTMENTS, LP (2.36M shares), and ALKEON CAPITAL MANAGEMENT LLC (2.21M shares).
This table shows the top 212 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.